key: cord-1052766-234pvb5y
authors: Jahromi, Alireza Hamidian; Stoehr, Jenna Rose
title: Caution Advised When Considering “Exceptional” Extended or Single Dose COVID-19 Vaccination Strategies
date: 2021-02-19
journal: Travel Med Infect Dis
DOI: 10.1016/j.tmaid.2021.101994
sha: 4094acf67558b9794c604d074a8301171e6800f6
doc_id: 1052766
cord_uid: 234pvb5y

nan

We read with interest the recently published editorial in The Lancet Infectious Diseases endorsing the current UK policy, proposed by UK chief medical officers, 1 for extending the Pfizer-BioNTech recommended COVID-19 vaccination dosing interval from 3-4 weeks to a 12 week period in order to prioritize single dose mass vaccination of the public due to constrains on vaccine supply. 2 In the current situation, with more than 3800 and 1280 daily COVID-19 related deaths in the United States and UK on the day this editorial was published, the impact of cold weather in the northern hemisphere on spread of respiratory viruses, health care systems overloaded, and the emergence and spread of SARS-CoV-2 variants, exceptional vaccination policies individualized to particular countries may be warranted.

However, we would like to caution the medical community before rushing to conclusions and endorsing the current UK policy to extend the recommended vaccination dosing interval, even as an expedient, short-term decision. A significant portion of this argument centers on the Joint Committee on Vaccination and Immunization (JCVI)'s estimation of single-dose protection rate of 90%. It is important to understand that this efficacy rate was calculated based on a shorter interval (15-28 days since vaccination) than the efficacy rate reported in the Pfizer-BioNTech data of 52.4%. 3, 4 The recalculation is not entirely valid, as it introduces an element of selection bias and misappropriates the trial data, as a one-dose regimen was not intended to be studied. It also does not allow for any understanding of the durability of single-dose immunity. While the length of provided protection with one or two doses of vaccines remains a matter of speculation, the second booster dose of vaccine has been demonstrated to induce higher antibody production. 5 As such, the two-dose regimen has a higher chance to induce longer lasting immunity.

Extending the vaccination dosing interval may decrease the two-dose vaccination efficacy of 95% 4 and durability of immunity. In addition, the risk of behavior change (use of personal protection equipment 

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated. 

Declarations Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated. There were no sources of funding for this article.

An exceptional vaccination policy in exceptional circumstances

Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines | Department of Health (health-ni.gov.uk), accessed on

Optimising the COVID-19 vaccination programme for maximum short-term impact -GOV.UK (www.gov.uk), website accessed on

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults